Repotrectinib (TPX-0005), another multi-kinase inhibitor that targets NTRK, ALK, JAK2/STAT, and Src/FAK rearrangements, has recently received FDA approval for ROS1 fusion-positive NSCLC and remains an area of interest in the management of ALK-positive NSCLC. Here, SRC is linked to non-small cell lung carcinoma.